Published in Medical Letter on the CDC and FDA, April 28th, 2002
"The incidence of fungal infections has increased dramatically, which has necessitated additional and prolonged use of the available antifungal agents," according to Dr. N. Jia and colleagues at Indiana University, Purdue University and Eli Lilly & Co. in Indianapolis, and the U.S. Centers for Disease Control and Prevention in Atlanta. "Increased resistance to the commonly used antifungal agents, primarily the azoles, has been reported, thus...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.